Ad
related to: cholesteryl ester vs cetp 10 gram- Dosing & Administration
Efficacy, Safety, and Dosing
Information for HCPs
- Trial Results
See Clinical Data
and Trial
- Co-Pay Program
Resources
to Support Your Patients
- Safety
Safety Profile - Learn About
Adverse Patient Reactions
- Dosing & Administration
Search results
Results From The WOW.Com Content Network
1071 n/a Ensembl ENSG00000087237 n/a UniProt P11597 n/a RefSeq (mRNA) NM_000078 NM_001286085 n/a RefSeq (protein) NP_000069 NP_001273014 n/a Location (UCSC) Chr 16: 56.96 – 56.98 Mb n/a PubMed search n/a Wikidata View/Edit Human Cholesteryl ester transfer protein (CETP), also called plasma lipid transfer protein, is a plasma protein that facilitates the transport of cholesteryl esters and ...
A CETP inhibitor is a member of a class of drugs that inhibit cholesterylester transfer protein (CETP). [1] [2] ...
Cholesteryl ester is transported from high-density lipoproteins (HDLs) to low-density lipoproteins (LDLs) and very low-density lipoproteins (VLDLs) with cholesteryl ester transfer protein (CETP). [5] The decrease in cholesteryl ester can lower HDL and increase LDL, which may be an indicator of cardiovascular problems, as indicated by ...
The cholesterol is converted to cholesteryl esters by the enzyme LCAT (lecithin-cholesterol acyltransferase) for sstorage. The cholesteryl esters can be transferred, with the help of CETP (cholesterylester transfer protein) in exchange for triglycerides, to other lipoproteins (such as LDL, VLDL, IDL). These other lipoproteins can be eventually ...
CETP inhibitors (cholesteryl ester transfer protein), 1 candidate is in trials. (Anacetrapib) It is expected that these drugs will mainly increase HDL while lowering LDL; Squalene synthase inhibitor; ApoA-1 Milano; Succinobucol (AGI-1067), a novel antioxidant, failed a phase-III trial.
Dalcetrapib [4] (INN, codenamed JTT-705) is a CETP inhibitor which was originally being developed by F. Hoffmann–La Roche until May 2012. [5] [6] DalCor Pharmaceuticals licensed dalcetrapib as a potential pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights into the development ...
Lipopolysaccharide, or LPS, is the major pathogenic factor on the cell wall of Gram-negative bacteria. Gram-positive bacteria has a similar component named Lipoteichoic acid, or LTA. HDL has the ability to bind LPS and LTA, creating HDL-LPS complexes to neutralize the harmful effects in the body and clear the LPS from the body. [9]
It converts free cholesterol into cholesteryl ester, a more hydrophobic form of cholesterol. This process sequesters cholesterol ester into the core of a lipoprotein particle, eventually making the newly synthesized HDL spherical and forcing the reaction to become unidirectional since the particles are removed from the surface.